No Data
No Data
Rodman & Renshaw Initiates Forte Biosciences(FBRX.US) With Buy Rating, Announces Target Price $4
Rodman & Renshaw analyst Elemer Piros initiates coverage on $Forte Biosciences(FBRX.US)$ with a buy rating, and sets the target price at $4.According to TipRanks data, the analyst has a success rate o
Express News | Camac Fund LP - Forte Biosciences' Board Will Be Expanded to Nine Seats, One Incumbent Director Will Resign, Two Directors Selected by Camac Fund
Express News | Camac Fund LP Says on Pursuant to Settlement Agreement Forte Biosciences Will Form Committee of Board to Explore Strategic Alternatives
Express News | Camac Fund LP Says on June 11, Entered Into Settlement Agreement With Forte Biosciences - SEC Filing
Forte Biosciences Initiated at Buy by Brookline Capital
Forte Biosciences Initiated at Buy by Brookline Capital
Brookline Capital Initiates Coverage On Forte Biosciences With Buy Rating, Announces Price Target of $4
Brookline Capital analyst Kumaraguru Raja initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy rating and announces Price Target of $4.